Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Kim

Medical Oncology Charlotte, NC Medical Doctor

NPI 1972688984 CMS profile 270777

1021 Morehead Medical Dr, Ste A, Charlotte, NC 28204

Open in the dashboard

General payments

$187,675

192 records reported · program years 2019–2025

Research payments

$22,735

Paid to them · 11 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,471,831 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Edward Kim of Charlotte, NC is reported in the CMS Open Payments database as having received $187,675 across 192 general payments and $22,735 in research payments paid to them. Separately, studies naming them as principal investigator received $1,471,831 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18,479 25
2024 General $5,861 26
2023 General $22,204 24
2022 General $26,103 22
2022 Research $4,394 4
2021 General $23,965 21
2021 Research $8,523 3
2020 General $22,886 20
2020 Research $2,298 2
2019 General $68,177 54
2019 Research $7,520 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Kim
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Edward Kim were reported at $18,479. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Edward Kim Medical Oncology median Middle half National median
2019 $68,177 $968 $140–$6,658 $163
2020 $22,886 $747 $102–$5,891 $114
2021 $23,965 $430 $50–$4,098 $132
2022 $26,103 $812 $127–$4,907 $149
2023 $22,204 $957 $144–$5,248 $160
2024 $5,861 $1,042 $149–$5,650 $164
2025 $18,479 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genentech, Inc. $41,850 26 payments
  2. AstraZeneca Pharmaceuticals LP $28,441 20 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $20,347 13 payments
  4. Genentech USA, Inc. $13,838 9 payments
  5. Boehringer Ingelheim International GmbH $12,819 8 payments
  6. AstraZeneca UK Limited $8,238 8 payments
  7. Boehringer Ingelheim Pharma GmbH & Co.KG $7,642 8 payments
  8. Roche Molecular Systems, Inc. $6,570 14 payments
  9. F. Hoffmann-La Roche AG $5,249 5 payments
  10. Partner Therapeutics, Inc. $5,002 9 payments
  11. Other $37,678 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $105,959 43 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $55,270 30 payments
  3. Travel and Lodging $19,161 37 payments
  4. Food and Beverage $5,040 71 payments
  5. Education $1,742 5 payments
  6. Grant $183 1 payment
  7. Charitable Contribution $180 4 payments
  8. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $139 1 payment
Products named General payments · program years 2019–2025
  1. TAGRISSO $35,013 21 payments
  2. GILOTRIF $24,746 16 payments
  3. TECENTRIQ $5,249 5 payments
  4. Tepotinib $4,550 1 payment
  5. LIBTAYO $4,058 2 payments
  6. IBRANCE $3,808 2 payments
  7. BIZENGRI $3,000 1 payment
  8. OFEV $2,860 1 payment
  9. Trodelvy $2,528 2 payments
  10. ALIMTA $1,750 1 payment
  11. Other $10,525 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $6,232 3 payments
  2. Celltrion, Inc. $4,954 2 payments
  3. Celgene Corporation $2,866 1 payment
  4. Takeda Pharmaceuticals U.S.A., Inc. $2,796 2 payments
  5. Genentech, Inc. $2,475 1 payment
  6. Novartis Pharma AG $1,875 1 payment
  7. F. Hoffmann-La Roche AG $1,537 1 payment

Records

203 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record